Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
Source: US Top News and Analysis
Related Posts
Here is why Nvidia’s partnership and investment in Marvell is such a big deal
Nvidia’s deal with Marvell Technology is yet another reason to stick with the AI giant’s…
Sánchez to Trump: Spain won’t ‘applaud those who set the world on fire just because they then show up with a bucket’
Spanish Prime Minister Pedro Sánchez has emerged as one of the European Union’s leading critics…
Friday’s big stock stories: What’s likely to move the market in the next trading session
Stocks continued their relief rally on Thursday as traders hoped the U.S.-Iran ceasefire would stick.…